Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;25(4):655-659.
doi: 10.1016/j.jsps.2017.04.041. Epub 2017 May 7.

The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury

Dejun Luo  1 , Guoyong Wu  1 , Yong Ji  1 , Zhaoyao Zhang  1 , Fayou He  1 , Xiaping Mou  1 , Qingmao Zhu  1 , Bo Yang  1
Affiliations

The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury

Dejun Luo et al. Saudi Pharm J. 2017 May.

Retraction in

Abstract

In the present study we compared the clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury. A total of 150 patients were enrolled in the present study and were divided into two groups with 75 patients in each group, receiving baclofen or tolperisone, respectively. We used Modified Ashworth Scale, Medical research council scale, Barthel Index, and Coefficient of efficacy to measure clinical efficacy. After 6-week treatment, both groups demonstrated significant improvement in muscle tone, muscle strength and functional outcome (Group I, 1.55 ± 0.053, 2.79 ± 0.032, 59.31 ± 1.32; Group II, 1.57 ± 0.053, 3.04 ± 0.032, 73 ± 1.32 respectively). There was no significant difference regarding improvement in muscle tone and muscle strength between the two groups (Group I, 1.055 ± 0.053 vs Group II, 1.57 ± 0.053; Group I, 2.79 ± 0.032 vs Group II, 3.04 ± 0.032, p > 0.05). However, the improvement in functional outcomes was greater in group II as compared to that in group I (Group I, 59.31 ± 1.32 vs Group II, 73 ± 1.32, p < 0.05). In addition, overall efficacy coefficient was greater for group II as compared to group I (Group I, 3.6 vs Group II, 2.3, p < 0.05). Group I had more side effects compared to Group II. Compared to baclofen, tolperisone offers greater improvement in activities of daily living compared to baclofen.

Keywords: Baclofen; Spasticity; Spinal cord injury; Tolperisone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Differences between the groups (a) Change in MAS, (b) Change in MRC score, (c) Change in BI index. Values are expressed as Mean + SEM.
See this image and copyright information in PMC

References

    1. Atta A., Mustafac G., Sheikh M.A., Shahid M., Xiao H. The biochemical significances of the proximate, mineral and phytochemical composition of selected vegetables from Pakistan. Mat. Sci. Pharma. 2017;1(1):06–09.
    1. Bennett D.J. Effects of baclofen on spinal reflexes and persistent inward currents in motoneurons of chronic spinal rats with spasticity. J. Neurophysiol. 2004;92:2694–2703. - PubMed
    1. Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther. 1987;67:206–207. - PubMed
    1. Bresolin N., Zucca C., Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial. Adv. Ther. 2009;26:563–573. - PubMed
    1. Collin C., Wade D.T., Davies S. The barthel ADL index: a reliability study. Int. Disab. Stud. 1988;10:61–63. - PubMed

Further reading

    1. Amanda V.D., Manasee V., Shah S. Clinically meaningful differences of the ashworth scale in post-Stroke upper limb spasticity. Neurotherapeutics. 2008;5:490.
    1. Bajaj P., Arendt-Nielsen L., Madeleine P. Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force: a double-blind randomized crossover control study. Eur. J. Pain. 2003;7:407–418. - PubMed
    1. Beckung E., Carlsson G., Carlsdotter S. The natural history of gross motor development in children with cerebral palsy aged 1 to 15 years. Dev. Med. Child Neurol. 2007;49:751–756. - PubMed
    1. Pandyan A., Gregoric M., Barnes M. Spasticity clinical perceptions, neurological realities and meaningful measurement. Disab. Rehab. 2005;27:2–6. - PubMed
    1. Quasthoff S., Möckel C., Zieglgänsberger W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci. Ther. 2008;14:107–119. - PMC - PubMed

Publication types

LinkOut - more resources